[en] Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.
Disciplines :
Dermatology
Author, co-author :
PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Aubin, Francois; Hôpital Saint Jacques, Besançon, France > Dermatologie
Humbert, Philippe; Hôpital Saint Jacques, Besançon, France > Dermatologie
Language :
English
Title :
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
Middleton M. R., Grob J. J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology 2000 18 1 158 166 2-s2.0-0033989205 (Pubitemid 30036349)
Bedikian A. Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A. C., DeConti R., Hersh E. M., Hersey P., Kirkwood J. M., Haluska F. G., Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. Journal of Clinical Oncology 2006 24 29 4738 4745 2-s2.0-33750600634 10.1200/JCO.2006.06.0483 (Pubitemid 46630937)
Henry C., Lapière M., Franchimont C., Piérard G. E., Lapière C. M., Ackerman A. B., Immunotherapy by dinitrochlorobenzene of melanomas of the skin. I- Methods, clinical effects and survival rates. Pathology of Malignant Melanoma 1981 New York, NY, USA Masson Publishing 367 371
Piérard G. E., Henry C., Franchimont C., Lapière M., Ackerman A. B., Lapière C. M., Ackerman A. B., Immunotherapy by dinitrochlorobenzene of melanomas of the skin. II- Histology of the cytotoxic effect. Pathology of Malignant Melanoma 1981 New York, NY, USA Masson Publishing 373 385
Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology 2005 23 10 2346 2357 2-s2.0-20244366111 10.1200/JCO.2005.00.240 (Pubitemid 46218728)
Komenaka I., Hoerig H., Kaufman H. L., Immunotherapy for melanoma. Clinics in Dermatology 2004 22 3 251 265 2-s2.0-3242668851 10.1016/j. clindermatol.2003.12.001 (Pubitemid 38950753)
Klein O., Ebert L. M., Nicholaou T., Browning J., Russell S. E., Zuber M., Jackson H. M., Dimopoulos N., Tan B. S., Hoos A., Luescher I. F., Davis I. D., Chen W., Cebon J., Melan-a-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research 2009 15 7 2507 2513 2-s2.0-65249149609 10.1158/1078-0432.CCR- 08-2424
Quatresooz P., Pierard G. E., gerald.pierard@ulg.ac.be Pierard-Franchimont C., Arrese J. E., Blaise G., Bourguignon R., Braham C., Broux M., Claessens N., Cornil F., Damseaux M., Darcis J. M., Dehavay J., Delvoye P., Devillers C., Fraiture A. L., Franchimont C., Goffin V., Henry F., Hermanns J. F., Lê T., Lesuisse M., Letot B., Martalo O., Mauhin F., Nikkels A., Paquet P., Rorive A., Szepetiuk G., Tassoudji N., Thirion L., Uhoda E., Uhoda I., Vandenbossche G., Willemaers V., Molecular pathways supporting the proliferation staging of malignant melanoma. International Journal of Molecular Medicine 2009 24 3 295 301 10.3892/ijmm00000232
Quatresooz P., Pierard-Franchimont C., Paquet P., Pierard G. E., Angiogenic fast-growing melanomas and their micrometastases. European Journal of Dermatology 2010 20 3 302 307 2-s2.0-77952872508 10.1684/ejd.2010.0929
Quatresooz P., pascale.quatresooz@chu.ulg.ac.be Piérard G. E., Malignant melanoma: from cell kinetics to micrometastases. American Journal of Clinical Dermatology 2011 12 2 77 86 10.2165/11318380-000000000-00000
Quatresooz P., Reginster M. -A., Piérard G. E., gerald.pierard@ulg.ac.be 'Malignant melanoma microecosystem': immunohistopathological insights into the stromal cell phenotype a review. Experimental and Therapeutic Medicine 2011 2 3 379 384 10.3892/etm.2011.221
Lorigan P., Eisen T., Hauschild A., Systemic therapy for metastatic malignant melanoma-From deeply disappointing to bright future? Experimental Dermatology 2008 17 5 383 394 2-s2.0-41949106667 10.1111/j.1600-0625.2007.00673. x (Pubitemid 351513952)
Sznol M., Betting on immunotherapy for melanoma. Current Oncology Reports 2009 11 5 397 404 2-s2.0-68949156442 10.1007/s11912-009-0053-z
Piérard-Franchimont C., Quatresooz P., Paquet P., Nikkels A. F., Piérard G. E., A range of targeted treatments using monoclonal antibodies in dermatology. Current and future practice. Revue Médicale de Liège 2009 64 334 338
Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
Korman A. J., Peggs K. S., Allison J. P., Checkpoint blockade in cancer immunotherapy. Advances in Immunology 2006 90 297 339 2-s2.0-33646794392 10.1016/S0065-2776(06)90008-X (Pubitemid 43765802)
Gajewski T. F., Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell and Melanoma Research 2010 23 5 580 581 2-s2.0-77956327518 10.1111/j.1755-148X.2010.00737.x
Laurent S., Carrega P., Saverino D., Piccioli P., Camoriano M., Morabito A., Dozin B., Fontana V., Simone R., Mortara L., Mingari M. C., Ferlazzo G., Pistillo M. P., CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Human Immunology 2010 71 10 934 941 2-s2.0-77956610892 10.1016/j.humimm.2010.07.007
Ku G. Y., Yuan J., Page D. B., Schroeder S. E. A., Panageas K. S., Carvajal R. D., Chapman P. B., Schwartz G. K., Allison J. P., Wolchok J. D., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival. Cancer 2010 116 7 1767 1775 2-s2.0-77950258677 10.1002/cncr.24951
Hodi F. S., Butler M., Oble D. A., Seiden M. V., Haluska F. G., Kruse A., MacRae S., Nelson M., Canning C., Lowy I., Korman A., Lautz D., Russell S., Jaklitsch M. T., Ramaiya N., Chen T. C., Neuberg D., Allison J. P., Mihm M. C., Dranoff G., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2008 105 8 3005 3010 2-s2.0-42949105127 10.1073/pnas.0712237105 (Pubitemid 351723658)
Hodi F. S., Oble D. A., Drappatz J., CTLA-4 blockage with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Proceedings of the National Academy of Sciences 2008 5 557 561
Kirkwood J. M., Lorigan P., Hersey P., Hauschild A., Robert C., McDermott D., Marshall M. A., Gomez-Navarro J., Liang J. Q., Bulanhagui C. A., Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clinical Cancer Research 2010 16 3 1042 1048 2-s2.0-76049092889 10.1158/1078-0432.CCR-09-2033
Camacho L. H., Antonia S., Sosman J., Kirkwood J. M., Gajewski T. F., Redman B., Pavlov D., Bulanhagui C., Bozon V. A., Gomez-Navarro J., Ribas A., Phase I/II trial of tremelimumab in patients with metastatic melanoma. Journal of Clinical Oncology 2009 27 7 1075 1081 2-s2.0-61449090474 10.1200/JCO.2008.19. 2435
Maker A. V., Yang J. C., Sherry R. M., Topalian S. L., Kammula U. S., Royal R. E., Hughes M., Yellin M. J., Haworth L. R., Levy C., Allen T., Mavroukakis S. A., Attia P., Rosenberg S. A., Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy 2006 29 4 455 463 2-s2.0-33747878218 10.1097/01.cji.0000208259. 73167.58 (Pubitemid 44288958)
Downey S. G., Klapper J. A., Smith F. O., Yang J. C., Sherry R. M., Royal R. E., Kammula U. S., Hughes M. S., Allen T. E., Levy C. L., Yellin M., Nichol G., White D. E., Steinberg S. M., Rosenberg S. A., Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research 2007 13 22 6681 6688 2-s2.0-36748999428 10.1158/1078-0432.CCR-07-0187 (Pubitemid 350206804)
Weber J. S., O'Day S., Urba W., Powderly J., Nichol G., Yellin M., Snively J., Hersh E., Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology 2008 26 36 5950 5956 2-s2.0-58049202334 10.1200/JCO.2008.16.1927
Wolchok J. D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., Waterfield W., Schadendorf D., Smylie M., Guthrie T., Grob J. J., Chesney J., Chin K., Chen K., Hoos A., O'Day S. J., Lebbé C., Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology 2010 11 2 155 164 2-s2.0-75249100054 10.1016/S1470-2045(09)70334-1
O'Day S. J., Maio M., Chiarion-Sileni V., Gajewski T. F., Pehamberger H., Bondarenko I. N., Queirolo P., Lundgren L., Mikhailov S., Roman L., Verschraegen C., Humphrey R., Ibrahim R., de Pril V., Hoos A., Wolchok J. D., Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology 2010 21 8 1712 1717 2-s2.0-77955256254 10.1093/annonc/mdq013
Thumar J. R., Kluger H. M., Ipilimumab: a promising immunotherapy for melanoma. Oncology 2010 24 14 1280 1288
Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology 1999 17 7 2105 2116 2-s2.0-0033024863 (Pubitemid 29318842)
Guillot B., Bessis D., Dereure O., Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opinion on Drug Safety 2004 3 6 579 587 2-s2.0-8844224058 10.1517/14740338.3.6.579 (Pubitemid 39530210)
Wyatt A. J., Leonard G. D., Sachs D. L., Cutaneous reactions to chemotherapy and their management. American Journal of Clinical Dermatology 2006 7 1 45 63 2-s2.0-33644555585 10.2165/00128071-200607010-00005
Piérard G. E., Paquet P., Piérard-Franchimont C., Rorive A., Quatresooz P., Cutaneous adverse reactions to chemotherapy and their management. Revue Medicale de Liege 2007 62 5-6 457 462 2-s2.0-35548940859 (Pubitemid 351525756)
Lowe M., Delman K. A., Ipilimumab for advanced melanoma: let's not throw caution to the winds. Oncology 2010 24 14 1296 1299
Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8372 8377 2-s2.0-0038153907 10.1073/pnas.1533209100 (Pubitemid 36842552)
Atria P., Phan G. Q., Maker A. V., Robinson M. R., Quezado M. M., Yang J. C., Sherry R. M., Topalian S. L., Kammula U. S., Royal R. E., Restifo N. P., Haworth L. R., Levy C., Mavroukakis S. A., Nichol G., Yellin M. J., Rosenberg S. A., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology 2005 23 25 6043 6053 2-s2.0-24944459890 10.1200/JCO.2005.06.205
Weber J., Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy 2009 58 5 823 830 2-s2.0-61349114199 10.1007/s00262-008-0653-8
Minor D. R., Chin K., Kashani-Sabet M., Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biotherapy and Radiopharmaceuticals 2009 24 3 321 325 2-s2.0-67650848410 10.1089/cbr.2008.0607
